MannKind Corporation
Clinical trials sponsored by MannKind Corporation, explained in plain language.
MannKind Corporation
MNKD
NASDAQ
Biopharmaceutical company known for inhaled insulin products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New inhaled insulin combo aims to simplify diabetes care for teens Results expected Mar 2027 (estimated)